EIF2AK2 and invasive breast carcinoma: According to The Human Protein Atlas (https://www.proteinatlas.org/ (accessed on 4 December 2022)), the 12-year survival rate for patients with invasive breast cancer with low PKR expression is approximately 70%, whereas the 12-year survival rate for patients with high PKR expression is approximately 30%.